Latex Agglutination Test Kits Market Forecasts from 2023 to 2028

The latex agglutination test kits market is estimated to grow at a CAGR of 4.49% during the forecast period.

Latex agglutination is used to detect antibodies and microorganisms. The diversified application of latex tests in antigens detection coupled with rising cases of infections due to changing lifestyles is expected to propel the latex agglutination market size. Moreover, the recent technological advancements and increased awareness among people about the effects of the adverse antigen are driving more people to get tested thereby boosting the latex agglutination market size in the coming years.

MARKET DRIVERS:

Wider application areas including antibody detection to raise the scope.

Latex agglutination tests are used to detect antibodies and antigens for multiple purposes widening the latex agglutination market scope. The antigens are detected for cryptococcus neoformans in cerebrospinal fluid or serum. Moreover, they are widely used for the detection of C-reactive protein, the detection of antistreptolysin O antibody, and beta-hemolyticStreptococcus. It is also used for the detection of capsular antigens such as pneumococcus, Haemophilus influenzae, and Meningococcus. Latex tests are being developed for implementation in more organisms such as rotavirus, clostridium difficile, and Escherichia coli from E coli. It confirms the presence of pathogen-specific antigens in the body or the specimen. These diversified applications of latex tests are the major growth drivers of the latex agglutination test kits market.

Rising prevalence of infectious diseases

Antigens or antibodies cause infections and numerous types of diseases. With the rise in infectious diseases and the application of latex tests in detecting antigen-causing infections is contemplated to boost the latex agglutination tests kit market. According to data by CDC, around 36, 000 people die from influenza and pneumonia every year in the US and 50, 000 new cases of HIV are reported in the US annually. The measles and mumps cases reported worldwide are 123, 174 and 241, 406 respectively as per the reports of the World Health Organization. The huge case of antigens causing infection and disease widens the potential of the latex agglutination market size.

Rising cases of rheumatoid arthritis

Rheumatoid arthritis can be diagnosed with polystyrene latex particles serving as carriers of fraction II of serum in an agglutination reaction with the patient’s serum. The rising case of rheumatoid arthritis among people in the aging population is anticipated to propel the latex agglutination test kits market. According to the June 2023 data released by the World Health Organization (WHO), globally over 18 million people were recorded to be living with rheumatoid arthritis in 2019. The source further added that about 70% of the people with the ailment are women, out of which 55% are older than 55 years. The leading cause of the musculoskeletal problem is population growth and aging resulting in more people getting lifelong disability. The rising cases of arthritis and the benefit of latex tests are contemplated to bolster the latex agglutination market size.

Rising Awareness among People about Infectious Diseases

There is rising awareness and knowledge among people about the adverse effects of antigens and antibodies which can be tested using latex agglutination kits thereby propelling the latex agglutination test kits market. Various awareness programs have been initiated to create such awareness for instance, the National Aids Control Organization of India launched an awareness program to raise awareness about its occurrence and spread. In July 2023, the California Department of Public Health released an update to the Community Rapid Testing Program to improve the equitable distribution of testing resources. These programs coupled with more adoption of latex agglutination test kits are expected to drive the market growth.

Research and Investments in the Field to propel the market growth.

The recent research and investments to enhance the latex tests are driving the latex agglutination test kits market. For instance, Momentum Technologies Laboratories expanded its client capabilities by investing $1 million in 1, 200 square feet testing lab and new equipment in 2019. This investment broadened the production of special latex equipment such as a mechanical stability tester, centrifuge, viscometer, and atomic absorption metals tester. Moreover, the latex agglutination kits give the result within 15 minutes to 1 hour of duration which is more efficient as compared to other antigen and antibodies testing mechanisms. The expansion in the market coupled with the efficiencies is anticipated to boost the latex agglutination test kits market.

North America is an expected dominant market.

The North American region is expected to dominate the latex agglutination test kits market during the forecast period. The factors attributing to significant share are technological advancements and rapid adoption of smart diagnostic test centers, coupled with increased awareness among people about diagnostic tests. According to the CDC, nearly 330000 Clinical Laboratory Improvements Amendments (CLIA) certified laboratories across the US. Moreover, the presence of leading companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, Arlington Scientific, and Hardy Diagnostics is further expected to boost the latex agglutination test kit market in the region in the coming years.

Latex Agglutination Test Kits Market Players

• Atlas Medical GmbH, founded in 1996 is one of the leading manufacturers and suppliers of diagnostic kits and reagents. The company provides turbidimetric latex kits to detect and quantify antigens in human stool samples.
• Thermo Fisher Scientific Incis an America-based global company which provides solutions in scientific instruments, reagents, consumables, and software services. The testing kits offered by the company are the legionella latex test kit, Xpect Rotavirus test, Xpect Giardia Test, Remel RPR antigen test kit, and others.
• HiMedia Laboratories, founded in 1976 is a leading biotechnology company that provides solutions in microbiology, cell biology, molecular biology, lab chemicals, and labware in industry, clinical, food, dairy, and water sector.

Key Market Developments

• In June 2022, Diagnostic BioSystems (DBS) entered into an expansion agreement with Thermo Fisher Scientific by offering 40 additional IHC primary antibodies to CROs, academic research, and clinical laboratories.
• In June 2022, Bio-Rad Laboratories launched two new diagnostic products in synthetic negative run control to control the tick-borne, meningitis, and sexually transmitted infections products, and hospital-associated infections negative run control.

Segmentation:

By Type

• ELISA
• Hemaggluniation Inhibition
• Serum Neutralization
• Indirect Fluorescent Antibody Test

By Application

• Diagnostic Centers
• Specialty Clinics
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others